Intestinal pseudo-obstruction.
D000293:Adolescent; D000328:Adult; D000686:Amyloidosis / Q000150:complications; D000978:Antiparkinson Agents / Q000009:adverse effects; D002400:Cathartics / Q000009:adverse effects; D014355:Chagas Disease / Q000150:complications; D003093:Colitis, Ulcerative / Q000000981:diagnostic imaging; D003106:Colon / Q000294:innervation; D003109:Colonic Diseases, Functional / Q000000981:diagnostic imaging* / Q000209:etiology; D003424:Crohn Disease / Q000000981:diagnostic imaging; D004402:Dysautonomia, Familial / Q000150:complications; D005260:Female; D005730:Ganglionic Blockers / Q000009:adverse effects; D006801:Humans; D007008:Hypokalemia / Q000150:complications; D007415:Intestinal Obstruction / Q000000981:diagnostic imaging* / Q000209:etiology; D007418:Intestinal Pseudo-Obstruction / Q000000981:diagnostic imaging; D007676:Kidney Failure, Chronic / Q000150:complications; D007855:Lead Poisoning / Q000150:complications; D008297:Male; D009223:Myotonic Dystrophy / Q000150:complications; D009230:Myxedema / Q000150:complications; D010276:Parasympatholytics / Q000009:adverse effects; D011859:Radiography; D012595:Scleroderma, Systemic / Q000150:complications; D013564:Sympathetic Nervous System / Q000503:physiopathology; D013577:Syndrome
D000978:Antiparkinson Agents; D002400:Cathartics; D005730:Ganglionic Blockers; D010276:Parasympatholytics